Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
Guntram Schernthaner,1 Sarah Jarvis,2 Chaim Lotan,3 Martin Prázný,4 Christoph Wanner,5 Thomas C Wascher6 1Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria; 2Richford Gate Medical Practice, London, UK; 3Cardiovascular Division, Heart Institute, Hadassah-Hebrew U...
Main Authors: | Schernthaner G, Jarvis S, Lotan C, Prázný M, Wanner C, Wascher TC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-01-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/advances-in-the-management-of-cardiovascular-risk-for-patients-with-ty-peer-reviewed-article-TCRM |
Similar Items
-
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
by: Schernthaner G, et al.
Published: (2017-12-01) -
SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01) -
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
by: Alaaeldin Bashier, et al.
Published: (2019-09-01) -
Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
by: Liwen Bao, et al.
Published: (2021-09-01) -
[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)